title: Induction of miR-137 by Isorhapontigenin (ISO) Directly Targets Sp1 Protein Translation and Mediates Its Anticancer Activity Both In Vitro and In Vivo.
abstract: Our recent studies found that isorhapontigenin (ISO) showed a significant inhibitory effect on human bladder cancer cell growth, accompanied with cell-cycle G0-G1 arrest as well as downregulation of Cyclin D1 expression at transcriptional level via inhibition of Sp1 transactivation in bladder cancer cells. In the current study, the potential ISO inhibition of bladder tumor formation has been explored in a xenograft nude mouse model, and the molecular mechanisms underlying ISO inhibition of Sp1 expression and anticancer activities have been elucidated both in vitro and in vivo. Moreover, the studies demonstrated that ISO treatment induced the expression of miR-137, which in turn suppressed Sp1 protein translation by directly targeting Sp1 mRNA 3'-untranslated region (UTR). Similar to ISO treatment, ectopic expression of miR-137 alone led to G0-G1 cell growth arrest and inhibition of anchorage-independent growth in human bladder cancer cells, which could be completely reversed by overexpression of GFP-Sp1. The inhibition of miR-137 expression attenuated ISO-induced inhibition of Sp1/Cyclin D1 expression, induction of G0-G1 cell growth arrest, and suppression of cell anchorage-independent growth. Taken together, our studies have demonstrated that miR-137 induction by ISO targets Sp1 mRNA 3'-UTR and inhibits Sp1 protein translation, which consequently results in reduction of Cyclin D1 expression, induction of G0-G1 growth arrest, and inhibition of anchorage-independent growth in vitro and in vivo. Our results have provided novel insights into understanding the anticancer activity of ISO in the therapy of human bladder cancer.
authors.affiliation: Nelson Institute of Environmental Medicine, New York University, School of Medicine, Tuxedo, New York. Department of Nephrology, Central Hospital of Wuhan, Wuhan, China.
authors.forename: Xingruo
authors.initials: X
authors.lastname: Zeng
authors.affiliation: Nelson Institute of Environmental Medicine, New York University, School of Medicine, Tuxedo, New York.
authors.forename: Zhou
authors.initials: Z
authors.lastname: Xu
authors.affiliation: Zhejiang Provincial Key Laboratory for Technology and Application of Model Organisms, School of Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
authors.forename: Jiayan
authors.initials: J
authors.lastname: Gu
authors.affiliation: Nelson Institute of Environmental Medicine, New York University, School of Medicine, Tuxedo, New York. Zhejiang Provincial Key Laboratory for Technology and Application of Model Organisms, School of Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
authors.forename: Haishan
authors.initials: H
authors.lastname: Huang
authors.affiliation: Nelson Institute of Environmental Medicine, New York University, School of Medicine, Tuxedo, New York.
authors.forename: Guangxun
authors.initials: G
authors.lastname: Gao
authors.affiliation: Nelson Institute of Environmental Medicine, New York University, School of Medicine, Tuxedo, New York.
authors.forename: Xiaoru
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Nelson Institute of Environmental Medicine, New York University, School of Medicine, Tuxedo, New York.
authors.forename: Jingxia
authors.initials: J
authors.lastname: Li
authors.affiliation: Nelson Institute of Environmental Medicine, New York University, School of Medicine, Tuxedo, New York.
authors.forename: Honglei
authors.initials: H
authors.lastname: Jin
authors.affiliation: Nelson Institute of Environmental Medicine, New York University, School of Medicine, Tuxedo, New York.
authors.forename: Guosong
authors.initials: G
authors.lastname: Jiang
authors.affiliation: Nelson Institute of Environmental Medicine, New York University, School of Medicine, Tuxedo, New York.
authors.forename: Hong
authors.initials: H
authors.lastname: Sun
authors.affiliation: Nelson Institute of Environmental Medicine, New York University, School of Medicine, Tuxedo, New York. chuanshu.huang@NYUMC.org.
authors.forename: Chuanshu
authors.initials: C
authors.lastname: Huang
mesh_terms: D020413:3' Untranslated Regions; D000818:Animals; D001483:Base Sequence; D001665:Binding Sites; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D000066630:Ectopic Gene Expression; D059585:G1 Phase Cell Cycle Checkpoints; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D051379:Mice; D035683:MicroRNAs / Q000737:chemistry / Q000235:genetics*; D014176:Protein Biosynthesis / Q000187:drug effects; D034622:RNA Interference; D012333:RNA, Messenger / Q000737:chemistry / Q000235:genetics; D016329:Sp1 Transcription Factor / Q000235:genetics* / Q000378:metabolism; D013267:Stilbenes / Q000494:pharmacology*; D047368:Tumor Burden / Q000187:drug effects / Q000235:genetics; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D023041:Xenograft Model Antitumor Assays
chemical_list: D020413:3' Untranslated Regions; C545567:MIRN137 microRNA, human; D035683:MicroRNAs; D012333:RNA, Messenger; D016329:Sp1 Transcription Factor; D013267:Stilbenes; C432307:isorhapontigenin
references.citation: J Biol Chem. 2012 Oct 12;287(42):35234-43
references.pmid: 22896709
references.citation: Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4109-17
references.pmid: 15217947
references.citation: Gastroenterology. 2013 Mar;144(3):624-635.e4
references.pmid: 23201162
references.citation: Carcinogenesis. 2013 Apr;34(4):803-11
references.pmid: 23275153
references.citation: Eur Urol. 2013 Jun;63(6):1091-100
references.pmid: 23200812
references.citation: Oncotarget. 2013 May;4(5):665-76
references.pmid: 23714687
references.citation: Mol Cancer Ther. 2013 Aug;12(8):1492-503
references.pmid: 23723126
references.citation: Mol Cancer Ther. 2013 Nov;12(11):2483-93
references.pmid: 24030632
references.citation: Mol Cell Biol. 2014 Jul;34(13):2382-95
references.pmid: 24732804
references.citation: Oncotarget. 2014 Jul 15;5(13):5113-24
references.pmid: 24970808
references.citation: Toxicol Appl Pharmacol. 2014 Sep 15;279(3):322-30
references.pmid: 24998975
references.citation: Tumour Biol. 2014 Sep;35(9):9131-8
references.pmid: 25027394
references.citation: PLoS One. 2014;9(10):e109734
references.pmid: 25330156
references.citation: Oral Oncol. 2014 Nov;50(11):1062-71
references.pmid: 25127200
references.citation: Oncotarget. 2015 Jan 1;6(1):522-36
references.pmid: 25402510
references.citation: J Cancer Res Clin Oncol. 2015 May;141(5):785-95
references.pmid: 25342326
references.citation: Clin Cancer Res. 2015 Aug 15;21(16):3783-93
references.pmid: 25977341
references.citation: Cancer Res. 2000 Mar 15;60(6):1546-51
references.pmid: 10749121
references.citation: Phytochemistry. 2000 Aug;54(8):875-81
references.pmid: 11014282
references.citation: Cancer Res. 2001 May 15;61(10):4143-54
references.pmid: 11358838
references.citation: J Biol Chem. 1992 Sep 5;267(25):17944-8
references.pmid: 1381357
references.citation: Ann Urol (Paris). 1992;26(5):281-93
references.pmid: 1485797
references.citation: J Gerontol A Biol Sci Med Sci. 1996 Jan;51(1):B66-75
references.pmid: 8548503
references.citation: Nucleic Acids Res. 1999 Aug 1;27(15):2991-3000
references.pmid: 10454592
references.citation: Cell. 2005 Jan 14;120(1):15-20
references.pmid: 15652477
references.citation: Cancer Res. 2005 Feb 1;65(3):1007-17
references.pmid: 15705902
references.citation: Genomics. 2005 May;85(5):551-6
references.pmid: 15820306
references.citation: Breast Cancer Res Treat. 2011 Aug;128(3):891-8
references.pmid: 21465167
references.citation: Mol Carcinog. 2011 Sep;50(9):655-67
references.pmid: 21268135
references.citation: Cell Signal. 2012 Jun;24(6):1229-40
references.pmid: 22360859
references.citation: PLoS One. 2012;7(6):e39102
references.pmid: 22723937
references.citation: J Natl Cancer Inst. 2006 Jun 21;98(12):855-68
references.pmid: 16788159
references.citation: J Cell Biochem. 2006 Nov 1;99(4):1010-20
references.pmid: 16475165
references.citation: Biochem Biophys Res Commun. 2007 Feb 2;353(1):86-91
references.pmid: 17161377
references.citation: Cancer Res. 2007 Mar 15;67(6):2816-23
references.pmid: 17363604
references.citation: Mol Cancer Ther. 2007 Mar;6(3):1022-30
references.pmid: 17363495
references.citation: Cancer Res. 2007 Nov 15;67(22):11001-11
references.pmid: 18006846
references.citation: Cancer Res. 2008 Jul 1;68(13):5345-54
references.pmid: 18593936
references.citation: Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9319-24
references.pmid: 18591662
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1648-52
references.pmid: 18628415
references.citation: Adv Enzyme Regul. 2008;48:189-208
references.pmid: 18187045
references.citation: Blood. 2009 Jun 18;113(25):6411-8
references.pmid: 19211935
references.citation: Carcinogenesis. 2009 Jul;30(7):1193-201
references.pmid: 19406933
references.citation: Lancet. 2009 Jul 18;374(9685):239-49
references.pmid: 19520422
references.citation: Cancer Biol Ther. 2009 Nov;8(22):2166-74
references.pmid: 19783902
references.citation: Cancer Res. 2010 Jan 15;70(2):813-23
references.pmid: 20068160
references.citation: J Biol Chem. 2010 Aug 13;285(33):25332-44
references.pmid: 20538607
references.citation: Cancer Sci. 2010 Jun;101(6):1463-70
references.pmid: 20384626
references.citation: J Cell Physiol. 2011 Mar;226(3):602-7
references.pmid: 20717966
references.citation: Int J Cancer. 2011 Mar 15;128(6):1269-79
references.pmid: 20473940
references.citation: Planta Med. 2002 Oct;68(10):916-20
references.pmid: 12391556
references.citation: BMC Cancer. 2002 Dec 10;2:35
references.pmid: 12475396
references.citation: Clin Cancer Res. 2003 Dec 15;9(17):6371-80
references.pmid: 14695137
references.citation: Cell. 2004 Jan 23;116(2):281-97
references.pmid: 14744438
references.citation: FEBS Lett. 2013 Jan 4;587(1):73-81
references.pmid: 23178712